Within the human body's invisible war against cancer lies a paradox: the very immune system meant to protect us is often turned against itself by tumors that recruit our own cells as shields. Researchers at IISER Kolkata have responded not with brute force, but with ingenuity — engineering friendly bacteria to infiltrate that shield, dismantle it, and reawaken the body's dormant defenses. This project, born from the collaboration of eleven undergraduate students, oncologists, survivors, and communities, asks whether the future of medicine might lie not in what we introduce from outside, but in
IISER Kolkata engineers 'friendly bacteria' as living cancer therapy
Converting friendly microbes into living, targeted medicines
Mark
So these bacteria are engineered to find tumors and then what—kill them?
Mimi
Not exactly. They're designed to disrupt the immune suppression happening around the tumor. The cancer hides behind these T regulatory cells that basically tell the immune system to stand down. The bacteria would interfere with that signal, essentially reactivating the body's own defenses.
Luke
But that's the theory. Has this actually worked in animal models or human tissue yet?
Mimi
The statement describes it as a proof of concept. They're presenting at iGEM in Paris, which is a competition for synthetic biology projects. So it's still in the research phase.
Mark
Why involve cancer survivors and NGOs if it's just lab work?
Mimi
Because they wanted to make sure the science was addressing real problems that patients actually face. They talked to surgeons about what barriers exist in current treatment, listened to survivors about what matters to them.
Luke
That's good practice, but it doesn't tell us whether the bacteria actually work in a living system. The human practices piece is important for design, but it's not the same as efficacy data.
Mark
What's the detection system they mentioned?
Mimi
A way to monitor whether the therapy is actually working—to track the progress of the treatment in real time.
Luke
Again, that's the goal. But I don't see specifics about how it works or what it measures.
Mark
So this is India's contribution to synthetic biology?
Mimi
This particular team is, yes. Eleven undergraduates doing world-class research. That's the point they're making—that India's youth can compete globally in this field.
Luke
They can, and this project shows ambition and creativity. But let's be clear: this is a student competition entry, not a clinical trial. The real test comes much later.
The Pulse
- Tumors actively recruit immune cells called Tregs to silence the body's defenses, rendering chemotherapy and immunotherapy far less effective for many patients.
- IISER Kolkata's ReSET project engineers normally harmless gut bacteria into targeted living medicines capable of detecting tumors and dismantling their protective shield.
- A dual therapeutic-and-diagnostic system means the treatment doesn't just act — it also monitors its own progress in real time, a significant leap beyond conventional single-intervention approaches.
- Eleven undergraduates drove this research not from a distance but in dialogue — consulting oncologists, cancer survivors, NGOs, and patient groups to ensure the science was ethically and socially grounded.
- Still a proof of concept, the project heads to the iGEM Grand Jamboree in Paris in October 2025, where India's young synthetic biologists will test their work against the world's best.
Within the human body's invisible war against cancer lies a paradox: the very immune system meant to protect us is often turned against itself by tumors that recruit our own cells as shields. Researchers at IISER Kolkata have responded not with brute force, but with ingenuity — engineering friendly bacteria to infiltrate that shield, dismantle it, and reawaken the body's dormant defenses. This project, born from the collaboration of eleven undergraduate students, oncologists, survivors, and communities, asks whether the future of medicine might lie not in what we introduce from outside, but in what we coax to life from within.
Cancer's most insidious trick is not merely growth — it is concealment. Tumors enlist a class of immune cells known as T regulatory cells, or Tregs, to actively suppress the body's defenses, which is why so many patients find that standard treatments eventually lose their grip. The cancer isn't just advancing; it is silencing the very system designed to stop it.
A team at the Indian Institute of Science Education and Research in Kolkata has chosen an unconventional path in response. Rather than targeting the tumor directly, they are reprogramming bacteria — ordinarily benign residents of the human body — to become living, targeted medicines. These engineered microbes would seek out tumors, dismantle the Treg shield, and rouse the immune system back into action from the inside. The project is called ReSET, shorthand for Reprogramming the Suppressive Environment of Tumour Microenvironment.
What distinguishes ReSET is its dual architecture: the bacteria themselves form one layer of the therapy, while a companion detection system monitors the treatment's effectiveness in real time. The result is something closer to a living diagnostic-therapeutic partnership than a conventional drug.
Equally notable is how the science was shaped. Eleven undergraduate students led the work, but they moved beyond the laboratory — meeting with oncologists, listening to cancer survivors, partnering with NGOs, and running awareness campaigns in schools. Those conversations left their mark on the therapy's design, grounding it in both scientific rigor and human relevance.
The project remains a proof of concept, not yet a treatment. But in October 2025, the team will carry it to Paris for the iGEM Grand Jamboree, the world's foremost synthetic biology competition — a moment that will measure what began quietly in Kolkata against the most ambitious research happening anywhere on earth.
Cancer has a way of hiding. The tumor wraps itself in a cloak of immune cells called T regulatory cells—Tregs—that actively suppress the body's natural defenses. This is why so many patients find that standard treatments like chemotherapy or immunotherapy hit a wall. The cancer isn't just growing; it's actively silencing the immune system that should be fighting it.
A team at the Indian Institute of Science Education and Research in Kolkata has taken an unconventional approach to this problem. Rather than attacking the cancer directly with drugs or radiation, they are engineering bacteria—the kind normally thought of as friendly microbes in the human body—to become living medicines. These modified bacteria would be designed to detect tumors, disrupt the protective shield of Tregs, and essentially wake up the immune system to recognize and fight the cancer from within.
The project, called ReSET (Reprogramming the Suppressive Environment of Tumour Microenvironment), represents a shift in how researchers think about cancer therapy. Instead of a single external intervention, the team is creating a dual system: the engineered bacteria themselves, plus a detection mechanism to monitor how well the therapy is working. Together, these form what the institute describes as a combined therapeutic and diagnostic approach—a way to both treat cancer and track the treatment's progress in real time.
What makes this work distinctive is not just the science but how it was developed. Eleven undergraduate students led the research, but they did not work in isolation. They spent time with oncologists and surgeons, spoke with cancer survivors, partnered with NGOs focused on cancer care, and organized awareness campaigns in schools. They collaborated with hair donors and patient support groups. These conversations shaped the therapy at every stage, ensuring it was not only scientifically sound but also ethically grounded and socially relevant to the people it might one day help.
The team's ambition is clear. By targeting the Tregs pathway with engineered bacteria, they believe they can create an entirely new class of cancer treatment—one that fundamentally changes how we approach the disease. The bacteria would work inside the patient's body, making the therapy potentially safer and more effective than current options. It is, in essence, turning the body's own microbial ecosystem into a tool for healing.
This work remains a proof of concept, not yet a treatment available to patients. But the team sees it as evidence of something larger: that India's young researchers can compete at the highest levels of synthetic biology. In October 2025, the eleven students will travel to Paris to present their project at the iGEM Grand Jamboree, the world's largest synthetic biology competition. What began in a lab in Kolkata will be measured against the best work being done anywhere on the planet.
Notable Quotes
By targeting the Tregs pathway with engineered bacteria, we hope to bring forward a completely new class of cancer therapeutics, one that will revolutionise the way we treat cancer— IISER Kolkata research team
Want the full story?
Read the original at The Tribune ↗
Health & Medicine